These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 10626806

  • 1. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11.
    Gliniak B, Le T.
    Cancer Res; 1999 Dec 15; 59(24):6153-8. PubMed ID: 10626806
    [Abstract] [Full Text] [Related]

  • 2. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.
    Naka T, Sugamura K, Hylander BL, Widmer MB, Rustum YM, Repasky EA.
    Cancer Res; 2002 Oct 15; 62(20):5800-6. PubMed ID: 12384541
    [Abstract] [Full Text] [Related]

  • 3. Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors.
    Xiang H, Fox JA, Totpal K, Aikawa M, Dupree K, Sinicropi D, Lowe J, Escandón E.
    Oncogene; 2002 May 16; 21(22):3611-9. PubMed ID: 12032863
    [Abstract] [Full Text] [Related]

  • 4. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR, Shankar S, Chen X, Asim M, Srivastava RK.
    Cancer Res; 2003 Sep 01; 63(17):5390-400. PubMed ID: 14500373
    [Abstract] [Full Text] [Related]

  • 5. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
    Ravi R, Jain AJ, Schulick RD, Pham V, Prouser TS, Allen H, Mayer EG, Yu H, Pardoll DM, Ashkenazi A, Bedi A.
    Cancer Res; 2004 Dec 15; 64(24):9105-14. PubMed ID: 15604280
    [Abstract] [Full Text] [Related]

  • 6. The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo.
    Zhu H, Zhao F, Yu S, He J, Deng L, Yi C, Huang Y.
    Int J Mol Med; 2012 Nov 15; 30(5):1087-94. PubMed ID: 22922573
    [Abstract] [Full Text] [Related]

  • 7. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts.
    El-Zawahry A, McKillop J, Voelkel-Johnson C.
    BMC Cancer; 2005 Jan 07; 5():2. PubMed ID: 15638938
    [Abstract] [Full Text] [Related]

  • 8. Supra-additive antitumor activity of 5FU with tumor necrosis factor-related apoptosis-inducing ligand on gastric and colon cancers in vitro.
    Shimoyama S, Mochizuki Y, Kusada O, Kaminishi M.
    Int J Oncol; 2002 Sep 07; 21(3):643-8. PubMed ID: 12168112
    [Abstract] [Full Text] [Related]

  • 9. Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells.
    Perego P, Ciusani E, Gatti L, Carenini N, Corna E, Zunino F.
    Biochem Pharmacol; 2006 Mar 14; 71(6):791-8. PubMed ID: 16438941
    [Abstract] [Full Text] [Related]

  • 10. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo.
    Fan QL, Zou WY, Song LH, Wei W.
    Cancer Chemother Pharmacol; 2005 Feb 14; 55(2):189-96. PubMed ID: 15290100
    [Abstract] [Full Text] [Related]

  • 11. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
    Allegrini G, Goulette FA, Darnowski JW, Calabresi P.
    Cancer Chemother Pharmacol; 2004 Mar 14; 53(3):261-6. PubMed ID: 14658007
    [Abstract] [Full Text] [Related]

  • 12. Synergism of CPT-11 and Apo2L/TRAIL against two differentially sensitive human colon tumor xenografts.
    Sugamura K, Gibbs JF, Belicha-Villanueva A, Andrews C, Repasky EA, Hylander BL.
    Oncology; 2008 Mar 14; 74(3-4):188-97. PubMed ID: 18714167
    [Abstract] [Full Text] [Related]

  • 13. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
    Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, Ross J, Koeppen H, Schwall R, Ashkenazi A.
    Cancer Res; 2004 Jul 15; 64(14):4900-5. PubMed ID: 15256461
    [Abstract] [Full Text] [Related]

  • 14. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
    Thai le M, Labrinidis A, Hay S, Liapis V, Bouralexis S, Welldon K, Coventry BJ, Findlay DM, Evdokiou A.
    Cancer Res; 2006 May 15; 66(10):5363-70. PubMed ID: 16707463
    [Abstract] [Full Text] [Related]

  • 15. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
    Britten CD, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD, Weitman S.
    Cancer Res; 1999 Mar 01; 59(5):1049-53. PubMed ID: 10070962
    [Abstract] [Full Text] [Related]

  • 16. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
    Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ.
    Clin Cancer Res; 2002 May 01; 8(5):994-1003. PubMed ID: 12006511
    [Abstract] [Full Text] [Related]

  • 17. Synergistic antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand combined with cisplatin in ovarian carcinoma cell lines in vitro and in vivo.
    Liu P, Mao H, Hou P.
    Int J Gynecol Cancer; 2006 May 01; 16(2):538-48. PubMed ID: 16681723
    [Abstract] [Full Text] [Related]

  • 18. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.
    Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ.
    Cancer Res; 2000 Feb 15; 60(4):847-53. PubMed ID: 10706092
    [Abstract] [Full Text] [Related]

  • 19. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.
    Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT.
    Cancer Res; 2001 Feb 15; 61(4):1645-51. PubMed ID: 11245478
    [Abstract] [Full Text] [Related]

  • 20. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
    Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC.
    Cancer Res; 2005 Jun 01; 65(11):4799-808. PubMed ID: 15930300
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.